A new report published in the Annals of Internal Medicine found that an estimated 1.3 million U.S. adults with diabetes rationed their insulin in the past year, representing 16.5% of those who use prescribed insulin.

Clinicians treating patients with COVID-19  who are at risk for progression to acute disease should be aware of potential drug–drug interactions when the oral antiviral treatment nirmatrelvir/ritonavir (Paxlovid—Pfizer) is administered to people taking common cardiovascular drugs, experts warn in a new Journal of the American College of Cardiology article.

Sandra Leal, APhA President, 2021–2022 shared words of gratitude as well as the importance and value of advocacy in her #APhA2022 Presidential Speech, “Amplifying Our Voice.”

Pharmacists are well aware that polypharmacy is a major issue among patients, especially older adults. Recent studies have estimated that approximately 36% of older adults take at least 5 prescription medications, and 67% take 5 or more medications or supplements, including OTCs.

To encourage the appropriate use of Pfizer’s COVID-19 antiviral drug nirmatrelvir/ritonavir (Paxlovid), the Institute for Safe Medication Practices (ISMP) released an alert for dispensing pharmacists.